S
Shahram Shahabi
Researcher at Eli Lilly and Company
Publications - 2
Citations - 118
Shahram Shahabi is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Cholinergic & Memantine. The author has an hindex of 1, co-authored 2 publications receiving 88 citations.
Papers
More filters
Journal ArticleDOI
Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modelling" of schizophrenia.
Gary Gilmour,Elsa Y. Pioli,Sophie Dix,Janice W. Smith,Michael W. Conway,Wendy T. Jones,Sally Loomis,Rebecca Mason,Shahram Shahabi,Mark D. Tricklebank +9 more
TL;DR: Despite nominally common mechanisms of action and often presumed biological equivalence, the NMDA antagonists tested produced very diverse effects on the expression of instrumental action, which implications with regard to animal modelling of schizophrenic psychotic symptoms are manifold.
Journal ArticleDOI
From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer’s disease
Alastair J. H. Brown,Sophie J. Bradley,Fiona H. Marshall,Giles A. Brown,K.A. Bennett,Jason M Brown,Julie E. Cansfield,David M. Cross,Chris de Graaf,Brian D. Hudson,Louis Dwomoh,João M. Dias,James C. Errey,Edward Hurrell,Jan Liptrot,Giulio Mattedi,Colin Molloy,Pradeep J. Nathan,Krzysztof Okrasa,Greg J. Osborne,J.C. Patel,Mark Pickworth,Nathan Robertson,Shahram Shahabi,Christoffer Bundgaard,Christoffer Bundgaard,Keith G. Phillips,Lisa M. Broad,Anushka V. Goonawardena,Stephen R. Morairty,Michael Browning,Francesca Perini,Gerard R. Dawson,John Francis William Deakin,Robert T. Smith,Patrick M. Sexton,Julie Warneck,Mary Vinson,Tim Tasker,Benjamin G. Tehan,Barry John Teobald,Arthur Christopoulos,Christopher J. Langmead,Ali Jazayeri,Robert M. Cooke,Prakash Rucktooa,Miles Congreve,Malcolm Peter Weir,Andrew B. Tobin +48 more
TL;DR: In this article, the authors designed the optimal properties for a well-tolerated M1-agonist with the potential to alleviate cognitive loss by taking a stepwise translational approach from atomic structure, cell/tissuebased assays, evaluation in preclinical species, clinical safety testing, and finally establishing activity in memory centers in humans.